Clinico-biological characteristics of TMA. (A) Trends in platelet and LDH levels during hospitalization. Eculizumab was administrated at days 13, 19, and 40 after onasemnogene abeparvovec infusion. (B) Peripheral smear shows 6% schistocytes (arrows) at D12 (original magnification, ×50). (C) TMA diffuse skin damage.